This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Greatbatch, Inc. Reports 2012 Third Quarter Results

Stocks in this article: GB

Greatbatch, Inc. (NYSE: GB), today announced results for its third quarter ended September 28, 2012:

  • Sales increased 22% over the prior year to $161.3 million and included 8% organic constant currency growth, as well as additional revenue from our acquisitions:
    • CRM/Neuromodulation product line revenue increased 13%.
    • Portable Medical product line benefiting from new product introductions.
    • 20% Vascular Access growth driven by commercialization of medical devices.
    • Orthopaedics constant currency revenue declined 6%; continues to be negatively impacted by operational issues at our Swiss facilities, which are aggressively being addressed.
  • Third quarter GAAP operating income of $2.1 million and diluted EPS loss of $0.32 per share decreased versus the prior year primarily due to charges incurred in connection with the consolidation of our Swiss Orthopaedic operations, which are ultimately expected to improve profitability beginning in 2013.
  • Adjusted operating income increased 27% over the prior year due to revenue growth and improved operating leverage. This increase resulted in adjusted diluted EPS of $0.46 per share for the third quarter, 12% above the prior year.
  • Cash flows from operations were $16 million for the third quarter, which enabled the Company to pay down an additional $6 million of long-term debt.
     
Three Months Ended
(Dollars in thousands, except per share data) September 28,   September 30,   %   June 29,   %
2012 2011 Change 2012 Change
Sales $ 161,340 $ 131,718 22% $ 166,548 -3%
 
GAAP Operating Income $ 2,127 $ 12,888 -83% $ 11,091 -81%
GAAP Operating Income as % of Sales 1.3% 9.8% 6.7%
 
Adjusted Operating Income* $ 18,664 $ 14,714 27% $ 18,589 0%
Adjusted Operating Income as % of Sales 11.6% 11.2% 11.2%
 
GAAP Diluted EPS $ (0.32) $ 0.30 N/A $ 0.16 N/A
Adjusted Diluted EPS* $ 0.46 $ 0.41 12% $ 0.43 7%
 
* Refer to Tables A and B at the end of this release for a reconciliation of GAAP to adjusted amounts.
 

CEO Comments

“During the quarter, we continued to drive growth in our core business and benefited from favorable market trends and new product introductions within our Portable Medical product line,” commented Thomas J. Hook, President & CEO, Greatbatch Inc. “Additionally, during the quarter, we continued to deepen our relationship with our larger OEM customers and successfully negotiated several long-term agreements which secured existing revenue streams, as well as expanded those relationships into other product lines. As we move forward, our goal is to continue to drive core growth through an increased focus on and investment in sales and marketing and the commercialization of our medical device pipeline. Additionally, we are focused on further improving profitability by leveraging our infrastructure and optimizing our R&D investment. I am pleased with the progress we have made on our strategic objectives and remain confident that these initiatives will improve the long-term growth and profitability of our Company.”

1 of 9

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs